
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
Advanced CancersLeukemiaThe goal of this clinical research study is to find the highest tolerable dose of T cells that can be given in combination with standard chemotherapy to patients with CLL. The safety of this combination will also be studied. The T cells being used in this study are a type of white blood cell that will be taken from your blood and then genetically changed in a laboratory. The process of changing the DNA (the genetic material of cells) of the T cells is called a gene transfer. After the gene transfer is complete, the genetically changed T-cells will be put back into your body. These T cells may help prevent cancer cells from coming back.

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic...
Chronic Lymphocytic LeukemiaThe purpose of this study is to find out what effects a new drug AT7519M has on chronic lymphocytic leukemia.

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic...
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaThis is a multi-center, open-label, dose escalation study.

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaTo compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
LeukemiaThe goal of Phase 1 of this clinical research study is to find the highest tolerable dose of bendamustine, combined with fludarabine and rituximab, that can be given to patients who have CLL that has been treated before. The goal of Phase 2 of this study is to find out if this drug combination can help to control the disease. The safety of this drug combination will also be studied.

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic...
Chronic Lymphocytic LeukemiaThe goal of this clinical research study is to learn if the combination of fludarabine, cyclophosphamide, alemtuzumab, and rituximab is effective in treating chronic lymphocytic leukemia in patients who have already been treated with chemotherapy. Primary Objectives: Evaluate the therapeutic efficacy, including the complete remission (CR), nodular partial remission (NPR), and partial remission (PR) rates (overall response) of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) in previously treated patients with Chronic Lymphocytic Leukemia (CLL). Second Objectives: Assess the toxicity profile of CFAR in previously treated patients with CLL. Monitor for infection and determine incidence and etiology of infection including cytomegalovirus in patients treated with CFAR. Evaluate molecular remission by polymerase chain reaction (PCR) for the clonal immunoglobulin heavy chain variable gene in responding patients treated with CFAR. Assess immune parameters, including pretreatment, during treatment, and post-treatment blood T-cell counts and subset distribution and serum immunoglobulin levels in patients treated with CFAR.

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents...
Indolent Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia1 moreThe primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk...
Acute Leukemias of Ambiguous LineagePhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia2 moreThis phase I trial studies the side effects and best dose of entinostat when given together with clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or bilineage/biphenotypic leukemia. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving entinostat with clofarabine may kill more cancer cells.

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Acute Myelocytic LeukemiaAcute Lymphocytic Leukemia11 moreThis study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma2 moreThe purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).